A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms FIL BVHD01
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 16 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.